Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects

Clinical and Translational Science

Volumn 9, Issue 4, 2016, Pages 221-227

  Kraft, W K ^a   Gilmartin, J H ^b   Chappell, D L ^b   Gheyas, F ^b   Walker, B M ^b   Nagalla, S ^a   Naik, U P ^a   Horrow, J C ^b   Wrishko, R E ^b   Zhang, S ^b   Anderson, M S ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; VORAPAXAR;

ADULT; AGED; ARTICLE; BLEEDING; BLEEDING TIME; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE; THROMBOCYTE AGGREGATION; TREATMENT DURATION;

EID: 84982239073     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12405     Document Type: Article

References (10)

1. Morrow, D.A. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366, 1404–1413 (2012).
2. Magnani, G. et al. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J. Am. Heart Assoc. 4, e001505 (2015).
3. Harker, L.A. & Slichter, S.J. The bleeding time as a screening test for evaluation of platelet function. N. Engl. J. Med. 287, 155–159 (1972).
4. Smith, C. Surgicutt: a device for modified template bleeding times. J. Med. Technol. 3, 29–31 (1986).
5. Kosoglou, T. et al. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. Eur. J. Clin. Pharmacol. 68, 291–300 (2012).
6. Chen, X. et al. Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects. Int. J. Clin. Pharmacol. Ther. 52, 889–899 (2014).
7. De Caterina, R. et al. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. Thromb. Haemost. 54, 528–532 (1985).
8. Payne, D.A., Hayes, P.D., Jones, C.I., Belham, P., Naylor, A.R. & Goodall, A.H. Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet action. J. Vasc. Surg. 35, 1204–1209 (2002).
9. De Kam, P.J. et al. The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin. Platelets 25, 480–487 (2014).
10. Kosoglou, T. et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur. J. Clin. Pharmacol. 68, 249–258 (2012).